Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
about
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsEfficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.The Language of Biosimilars: Clarification, Definitions, and Regulatory AspectsBiosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.A Comprehensive Review on Copemyl(®).CT-P13 in the treatment of rheumatoid arthritis.Biosimilars for psoriasis: clinical studies to determine similarity.Biosimilar biologic drugs: a new frontier in medical care.Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.Biosimilars Are Here: A Hospital Pharmacist's Guide to Educating Health Care Professionals on BiosimilarsA budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.
P2860
Q26748630-A3AC3336-1BB4-42A7-B974-4C59C0CB69ACQ31085610-0CC13919-A7BB-47DC-B20F-507B24CA2EE5Q33713261-3A86E3BD-14AB-41CF-A5EA-8D7116D5287EQ33721952-CFA28232-0E34-49B1-9721-6DBC6F5FECF0Q37616966-21BE838B-5AFE-45B3-A4A3-2EA848DA89EAQ37732903-4543C0B1-F892-4123-A939-9779885A8449Q38592363-A7C70D27-4B8E-4F65-B03C-792130EFFE02Q38650000-635C6397-64A7-44F2-8C3F-A7DC4BBD021FQ38676104-1A0E2633-E698-4EC3-A859-3FD61C72DCC0Q38957406-2C640FEC-192E-43CA-9410-16523B3B65A9Q39200937-242C9FAE-6708-4B5F-BD94-2FB2991B6DCCQ40851924-B7AD8875-26E3-4459-B759-BB9942B15DFCQ42385440-8293B457-2967-4E98-A10C-7B92720DDD91Q43926604-3BA66E6E-5130-4F7C-9A8D-B11C80E8CA50Q47114415-D5627898-B66B-45E0-A1CB-01541A24A868
P2860
Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Statistical and regulatory con ...... y of biological drug products.
@ast
Statistical and regulatory con ...... y of biological drug products.
@en
type
label
Statistical and regulatory con ...... y of biological drug products.
@ast
Statistical and regulatory con ...... y of biological drug products.
@en
prefLabel
Statistical and regulatory con ...... y of biological drug products.
@ast
Statistical and regulatory con ...... y of biological drug products.
@en
P2093
P2860
P1476
Statistical and regulatory con ...... y of biological drug products.
@en
P2093
Lászlo Tóthfalusi
László Endrényi
Shein-Chung Chow
P2860
P2888
P356
10.1007/S10198-014-0589-1
P478
15 Suppl 1
P577
2014-05-16T00:00:00Z